
|Articles|December 1, 2004
Novel filler found safe, durable
San Diego - Results from a U.S. Food and Drug Administration pivotal trial demonstrate that the injectable wrinkle filler Artecoll, composed of polymethylmethacralate (PMMA) microspheres (20 percent) suspended in an ultra-purified collagen carrier (80 percent) is an equally safe, but longer-lasting, alternative to bovine collagen for the cosmetic correction of a variety of facial contour defects, Steven R. Cohen, M.D., tells Dermatology Times.
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Oruka Reports Positive Interim Phase 1 Data for ORKA-002, Advances ORKA-001
2
Recludix Pharma’s REX-8756 for Type 2 Inflammatory Diseases Enters First Human Trials
3
French Early Access Data on Dupilumab in Pediatric Atopic Dermatitis
4
Alpha Tau Submits First PMA Module to FDA for Novel cSCC Treatment, Alpha DaRT
5


















